Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 985-987

  Xu, Jian Wei ^a,b,c   Li, Cheng Guang ^a,c   Huang, Xin En ^a,c   Li, Ying ^a,c   Huo, Jie Ge ^b  

^a JIANGSU CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863075729     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Constam DB, Tobler AR, Rensing-Ehl A, et al (1995). Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J Biol Chem, 270, 26931-9.
2. Ino K, Bierman PJ, Varney ML, et al (1996). Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother, 43, 206-12.
3. Ishizuka M, Masuda T, Kanbayashis N, et al (1980).Effect of bestatin on mouse immune system and experimental murine tumors. Antibiotics, 33, 642-52.
4. Ishizuka M, Sato J, Sugiyama Y, et al (1980). Mitogenic effect of bestatin on lymphocytes. Antibiotics, 33, 653-62.
5. Ishizuka M,Takeuchi T, Umezawa H (1981). Activity of bestatin: Enhancenent of immune responses and antitumor In Small Molecular Immunomodifiers of Microbial Origin-Fundamental and Clinical Studies of Bestatin. Ed., H. Umezawa, pp. 17-38, Japan Scientific Societies Press, Tokyo.
6. Leuhauseng G, Schusterp DK, Vaith P, et al (1983). Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin. Biochem Pharmacol, 32, 1051-7.
7. Lin M, He J, Cai Z, et al (2001). Amiopeptidase inhihitor bestatin induces HL-60 cell apoptosis through activating caspase 3. Chin J Hematol, 22,348-50.
8. Mathe GB (1991). An aminopeptidase inhibitor with a multipharmacological funcfion. Biomed Pharmacother, 45, 49-54.
9. Noma T, Klein B, Cupissol D, et al (1984). Increased sensitivity of 1L2-dependent cultured T cells and enhancement of in vitro 1L2 production by human lymphocytes treated with bestatin. Int J Immunopharmacol, 6, 87-92.
10. Ozono S, Iwai A, Babayak S, et al (1990). Effects of bestatin on the host immunity in patients treated for urogenital cancer. Acta Oncol, 29,813-6.
11. Suda H, Aoyagi T, Takeuchi T, et al (1976). Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys, 117, 196-200.
12. Umezawa H, Aoyagi T, Suda H, et al (1976). Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. Antibiotics, 29, 97-9.
13. Umezawa H,Ishizuka M, Aoyagi T, et al (1976). Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. Antibiotics, 29, 857-9.
14. Wing EJ, Remington JS (1977). Cell-mediated immunity and its role in resistance to infection. West J Med, 126, 14-31.
15. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.